ABI-008 Trial in Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008
giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the
pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients
with metastatic breast cancer.